KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma
Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting
Immunocore reports fourth quarter and full year 2025 financial results and provides a business update
Immunocore to report fourth quarter and full year 2025 financial results and host call on February 25, 2025
LAURION Retains SMARTIR Marketing Ltd. to Drive Investor Awareness Ahead of Active 2026 Exploration Program
LaFleur Minerals Engages Leading Executive Search Firm to Recruit Senior Mining Executive as Company Advances Toward Gold Production
SAGA Metals Closes on Title Transfer Agreement to Expand Wolverine Heavy Rare Earth Element Project in Labrador-Grab Sample Assays Included up to 21.6% TREO
